Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > We're starting to get part of it...
View:
Post by JDavenport on Apr 19, 2022 6:44pm

We're starting to get part of it...

I've always claimed that the share price won't begin to rise until Bioasis accomplishes some stuff that makes the news in the biotech and financial media. (Making it in popular media would be even bigger, but that would require really substantial clinical accomplishment in such as areas as brain tumours, Alzheimer's, and such.)

This Fierce Pharma article about J&J and Bioasis is the beginning of that. The financial part isn't known and as a result the agreement didn't make news in the financial media, but Fierce Pharma (not Fierce Biotech) saw fit to report it.

And that's how it starts...

jd
Comment by cmonreally24 on Apr 19, 2022 6:58pm
This post has been removed in accordance with Community Policy
Comment by JDavenport on Apr 19, 2022 7:27pm
Sorry, cmonreally, there was no financial information because it was likely a material transfer agreement (MTA) as JNJ/Janssen's Macdonald discussed in the Sachs Associates Alzheiner's panel. If there was no financial aspect to the agreement then the financial media would have no interest, unless, I suppose, the stock starts to run with this name association and the validation of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities